ClinicalTrials.gov
ClinicalTrials.gov Menu

Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome (STAIR-SLOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01356420
Recruitment Status : Unknown
Verified September 2012 by Robert Steiner, Oregon Health and Science University.
Recruitment status was:  Recruiting
First Posted : May 19, 2011
Last Update Posted : September 20, 2012
Sponsor:
Information provided by (Responsible Party):
Robert Steiner, Oregon Health and Science University

May 11, 2011
May 19, 2011
September 20, 2012
January 2011
January 2016   (Final data collection date for primary outcome measure)
To define the rate of progression of clinical and biochemical measures in patients with Smith Lemli-Opitz syndrome receiving dietary cholesterol supplementation. [ Time Frame: Once per year at annual study visit ]
This study will measure changes in whole body cholesterol pool size, 24S, cholesterol absorption and synthesis in relation with cholesterol intake and changes in clincal end-points.
Same as current
Complete list of historical versions of study NCT01356420 on ClinicalTrials.gov Archive Site
  • Correlate biochemical and clinical phenotypes [ Time Frame: Once per year at annual study visit ]
    To correlate biochemical and clinical phenotypes in SLOS subjects given dietary cholesterol with changes in whole body cholesterol pool size, and with its major determinants (cholesterol synthesis, absorption and intake).
  • Identify clinical or biochemical markers for future therapeutic trials. [ Time Frame: Once per year at annual study visit ]
    To identify clinical or biochemical markers that can be used as outcome measures in a future therapeutic trial.
  • Identify a biochemical marker that can be used for diagnostic testing or screening. [ Time Frame: Once per year at annual study visit ]
    To identify a biochemical marker that can be used for diagnostic testing or screening
  • Develop a registry and repository of biomaterials of SLOS patients [ Time Frame: each subject will be enrolled in the registry at the baseline/initial visit, if they choose to participate in this portion of the study ]
    To develop a registry of well characterized SLOS patients and to maintain a repository of biomaterials corresponding to these patients
Same as current
Not Provided
Not Provided
 
Sterol and Isoprenoid Disease Research Consortium: Smith-Lemli-Opitz Syndrome
Smith-Lemli-Opitz Syndrome: A Longitudinal Clinical Study of Patients Receiving Cholesterol Supplementation

The purpose of this study is to learn about Smith-Lemli-Opitz Syndrome (SLOS). SLOS is an inherited condition that is caused by the body not making an enzyme as it should. The body needs the enzyme to help make cholesterol. SLOS can cause many health problems including slow growth and development, eating disorders, sleep disorders, behavior disorders, and eye diseases. Severe SLOS leads to birth defects and mental retardation and in many cases early death. The investigators plan to measure cholesterol and other sterol levels, perform clinical observations, whole body testing and imaging (brain MRIs), to learn more about the disease and its progression, differences in the clinical features among individuals with SLOS, and look at the effect of cholesterol supplementation in this condition.

The study is an interventional study to characterize disease progression and correlations between clinical, biochemical and physiological features of the disease. The main hypothesis is that dietary cholesterol supplementation does not improve features of SLOS related to the brain (e.g. IQ, behavior).

Smith-Lemli-Opitz syndrome (SLOS) is a disorder of cholesterol synthesis, or production. It is caused by mutations in the DHCR7 gene which encodes for 7-dehydrocholesterol- Δ7-reductase, an enzyme necessary for the production of cholesterol in the body. Affected individuals exhibit multiple malformations and mental retardation. The features of SLOS are thought to be primarily related to cholesterol deficiency and accumulation of cholesterol precursors. However, the clinical phenotype is not well characterized, the biochemical pathogenesis is incompletely understood, and there is no proven therapy for this devastating condition. Thus our primary objective is to better define the clinical and biochemical phenotypes of the disease using a natural history study design. The study will contribute to creating a comprehensive SLOS patient registry, identify biomarkers that can be used for diagnostic testing, screening and outcome measures in future therapeutic trials. All patients with SLOS receive dietary cholesterol supplementation with the hope that cholesterol supplementation will improve the clinical manifestation of the disease. However, there is no evidence supporting a clinical benefit of cholesterol supplementation. Thus a secondary objective of the study is to determine if cholesterol intake correlates with changes in whole body cholesterol homeostasis and clinical end-points.
Interventional
Not Applicable
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Smith-Lemli-Opitz Syndrome
Dietary Supplement: Cholesterol supplementation
Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
Experimental: Cholesterol supplementation
All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
Intervention: Dietary Supplement: Cholesterol supplementation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
100
Same as current
Not Provided
January 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Confirmed diagnosis of Smith-Lemli-Opitz Syndrome (SLOS)
  • Males and females of all ages
  • Willing and able to travel to OHSU or another STAIR site

Exclusion Criteria:

  • Subject does not have Smith-Lemli-Opitz Syndrome (SLOS)
Sexes Eligible for Study: All
up to 85 Years   (Child, Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01356420
STAIR 7001
Yes
Not Provided
Not Provided
Robert Steiner, Oregon Health and Science University
Oregon Health and Science University
Not Provided
Principal Investigator: Robert Steiner, MD Oregon Health and Science University
Oregon Health and Science University
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP